Search

We retrospectively evaluated the utility "over D1" or D1 dissections on outcome of gastric cancer patients with subsequent postoperative chemoradiotherapy. Sixty-five patients with gastric adenocarcinoma treated with postoperative concurrent chemoradiotherapy were evaluated. Inclusion criteria were total or subtotal gastrectomy with a cut-point of =10 nodes dissected in the surgery without scheduled splenectomy and pancreatectomy. Nodal dissections grouped according to Japanese Research Society; N1 stations (1-6) as D1, and dissection of additional stations (7-9) as "over D1". The median follow-up was 30 months. Surgery was total gastrectomy in 32 patients and subtotal in 33. Nodal dissection was D1 in 36 (55.4%) patients and over D1 in 29 (44.6%). The 2-year overall, local recurrence free, distant metastasis free, and disease free survivals of the entire group of patients were 83.3%, 89.9%, 68.4%, 62.5% respectively. Two year distant metastasis free survival was %55 for D1 and %88.5 for "over D1" dissected patients (p= 0.06). Overall survival was significantly longer in "over D1" dissected patients (2 year overall survival: 72.3% for D1 and 96% for "over D1", p= 0.05). Moreover, disease specific survival was significantly longer in "over D1" dissected patients (2 year disease specific survival: 72.3% for D1 and 100% for "over D1", p= 0.02). No grade 3-4 acute or late toxicity was observed. In conclusion, our retrospective data showed that over D1 dissected patients treated with concomitant chemoradiotherapy seemed to gain additional survival benefit in comparison to D1 dissected patients in this retrospective cohort with no significant extra toxicity. [ABSTRACT FROM AUTHOR]

In this study, we evaluated the efficiency and the toxicity of three dimensional conformal hemithoracic radiotherapy (3DCHRT) after extra pleural pneumonectomy (EPP). The median age of 14 patients were 51 years (range, 33-61 years). Most commonly seen histopathology was epitheliod type (79%). According to American Joint Commission on Cancer (AJCC) 2002 staging system 9 cases (64%) were stage III. A total median dose of 50.4 Gy was applied to hemithoracic cavity. Eleven patients received adjuvant chemotherapy. 3DCHRT was generally well tolerated. The acute toxicities of 3DCHRT were grade I-II. After a median of 16 months follow-up, intrathoracic control was100%. Six patients (43%) developed abdominal relapse and one (7%) developed distant metastasis. Nine cases were dead with two of them being without the evidence of disease. Excellent local control with 3DCHRT after EPP seems to change the relapse patterns of MPM. More effective systemic treatment is needed to prevent the recurrences outside thorax. [ABSTRACT FROM AUTHOR]

In this study, we evaluated the efficiency and the toxicity of three dimensional conformal hemithoracic radiotherapy (3DCHRT) after extra pleural pneumonectomy (EPP). The median age of 14 patients were 51 years (range, 33-61 years). Most commonly seen histopathology was epitheliod type (79%). According to American Joint Commission on Cancer (AJCC) 2002 staging system 9 cases (64%) were stage III. A total median dose of 50.4 Gy was applied to hemithoracic cavity. Eleven patients received adjuvant chemotherapy. 3DCHRT was generally well tolerated. The acute toxicities of 3DCHRT were grade I-II. After a median of 16 months follow-up, intrathoracic control was100%. Six patients (43%) developed abdominal relapse and one (7%) developed distant metastasis. Nine cases were dead with two of them being without the evidence of disease. Excellent local control with 3DCHRT after EPP seems to change the relapse patterns of MPM. More effective systemic treatment is needed to prevent the recurrences outside thorax. [ABSTRACT FROM AUTHOR]

The aim of this study is to evaluate the treatment results of three dimensional conformal radiotherapy (3DCRT) and androgen deprivation therapy (ADT) in patients with clinically localized prostate cancer (CLPC). Between June 1998 and December 2011, 577 patients with the diagnosis of CLPC were treated. ADT was started 3 months prior to radiotherapy (RT). 3DCRT was delivered to prostate and the seminal vesicles (SV) to a total dose of 70Gy. Additionally, patients with lymph node (LN) positivity received 50.4Gy RT to pelvic LN's. Median follow up time was 65 months. Five-ten years overall survival (OS), cause specific survival (CSS), PSA relapse-free survival (PSA-RFS) and distant metastasis-free survival (DMFS) rates were 92-74%, 97-91%, 77-55% and 94-88%, respectively. OS was negatively affected from LN positivity (p< 0.001). In the subgroup of patients with GS= 8, there was no significant difference between < 1 years and = 1 years of ADT in terms of CSS, PSA-RFS and DMFS. OS was better in patients with < 1 years of ADT (p= 0.01). Five year OS (p= 0.02), CSS (p= 0.05), PSA-RFS (p= 0.01) and DMFS (p= 0.07) rates were inferior in the high risk group patients that used ADT = 1 year. Acute and late RTOG grade III/IV gastrointestinal system toxicity rates were 1.7% and 5% and acute and chronic RTOG grade III/IV genitourinary system toxicity rates were 1.4% and 5%, respectively. 3DCRT and ADT combination is an effective treatment modality with acceptable toxicities in patients with clinically localized prostate cancer. [ABSTRACT FROM AUTHOR]

Isolated adrenal metastasis from non-small cell lung cancer (NSCLC) is a rare event. Nonsurgical treatment of a solitary adrenal metastasis is associated with poor survival. However, in the aspect of long-term survival, the role of adrenalectomy for isolated metastasis is unclear. Here, we reported our experience with surgical treatment of solitary adrenal metastasis in patients with NSCLC whose primary tumor control were achieved and reviewed current literature. Between the 2001 and 2009, five patients underwent curative adrenalectomy (in 1 patient it was bilateral) for suspected solitary adrenal metastasis after surgical treatment of NSCLC. The pathologic examination confirmed in 3 cases a NSCLC metastasis while in 2 cases it was a benign lesion. In the follow-up period, all of the 3 patients with adrenal metastasis had recurrence of NSCLC. Recurrence was local (in the operated adrenal bed) in 2 patients. Palliative radiotherapy focalized to adrenal bed was given to one of the patient with local recurrence. This patient is currently alive 51 months after the adrenalectomy. The other patient with local recurrence died 24 months after the adrenalectomy. Recurrence was systemic (brain and contralateral adrenal gland) in 1 patient who was treated with contralateral adrenalectomy and surgical resection of the cranial metastasis followed by cranial radiotherapy. The patient who underwent bilateral adrenalectomy for metastatic lung cancer died of wide-spread metastatic disease, 79 months after the adrenalectomy. In conclusion, survival benefit can be obtained after complete resection of isolated adrenal metastasis in patients with NSCLC. Therefore, resection of isolated adrenal metastasis should be considered if the primary NSCLC is resectable. [ABSTRACT FROM AUTHOR]